Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: VNS003
MIFTS: 55

Venous Insufficiency

Categories: Blood diseases, Cardiovascular diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Venous Insufficiency

About this section

MalaCards integrated aliases for Venous Insufficiency:

Name: Venous Insufficiency 12 29 43 15 71 32
Peripheral Venous Insufficiency 12

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:10128
ICD9CM 34 459.81
MeSH 43 D014689
NCIt 49 C127822
SNOMED-CT 67 20696009
ICD10 32 I87.2
UMLS 71 C0042485
Sources

Summaries for Venous Insufficiency

About this section
Disease Ontology : 12 A vein disease that is characterized by impaired flow of blood through the veins.

MalaCards based summary : Venous Insufficiency, also known as peripheral venous insufficiency, is related to lipodermatosclerosis and post-thrombotic syndrome. An important gene associated with Venous Insufficiency is PLAT (Plasminogen Activator, Tissue Type), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Hesperidin and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include skin, heart and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Sources

Related Diseases for Venous Insufficiency

About this section

Diseases in the Venous Insufficiency family:

Chronic Venous Insufficiency

Diseases related to Venous Insufficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 470, show less)
# Related Disease Score Top Affiliating Genes
1 lipodermatosclerosis 32.7 VEGFA PLAT MMP1
2 post-thrombotic syndrome 31.9 VCAM1 SERPINE1 PLAT ICAM1 F5 F2
3 chronic venous insufficiency 31.2 VEGFA VCAM1 TIMP1 SERPINE1 SELP SELL
4 thrombophilia due to thrombin defect 30.5 SERPINE1 PLAT MTHFR F5 F2
5 relapsing-remitting multiple sclerosis 30.5 TIMP1 MMP9 ITGA4 ICAM1
6 chronic ulcer of skin 30.4 VEGFA MMP1 CRP
7 hemorrhoid 30.4 MMP9 F2 CRP
8 thoracic outlet syndrome 30.1 PLAT F2
9 aspiration pneumonia 30.0 ITGAM F2 CRP
10 telangiectasis 29.9 VEGFA NDP ELN
11 papilledema 29.9 VEGFA F2 CRP
12 purpura 29.8 VWF SELP F2 CRP
13 buerger disease 29.7 SERPINE1 PLAU MTHFR F2
14 pyoderma 29.7 MMP9 MMP1 CRP
15 arteriosclerosis obliterans 29.6 VCAM1 SELP MMP9 ICAM1
16 microvascular complications of diabetes 5 29.6 VEGFA VCAM1 SERPINE1 ICAM1
17 brain edema 29.6 VEGFA PLAT MMP9 CRP
18 endocarditis 29.6 VCAM1 SERPINE1 PLAT F2 CRP
19 skin disease 29.6 SELL MMP1 ICAM1 ELN CRP
20 intracranial hypertension 29.5 SERPINE1 MTHFR F5 F2
21 sudden sensorineural hearing loss 29.5 MTHFR F5 F2
22 hemangioma 29.5 VWF VEGFA MMP9 F2
23 primary progressive multiple sclerosis 29.5 VCAM1 TIMP1 SELL MMP9 ITGA4 ICAM1
24 osteoarthritis 29.4 TIMP1 MMP9 MMP1 CRP
25 hypothyroidism 29.4 VWF VEGFA SERPINE1 F2 CRP
26 portal hypertension 29.3 VWF VEGFA SERPINE1 F2 ELN
27 thrombophlebitis 29.3 VWF SERPINE1 SELP PLAT MTHFR F5
28 proteasome-associated autoinflammatory syndrome 1 29.3 VCAM1 SELP SELL MMP9 ICAM1 CRP
29 sleep apnea 29.3 VEGFA VCAM1 SELP ICAM1 CRP
30 dermatitis, atopic 29.3 VCAM1 TIMP1 SELP SELL ITGAM ICAM1
31 amaurosis fugax 29.3 SERPINE1 MTHFR MMP9 F5
32 vasculitis 29.2 VWF VCAM1 SELP SELL ITGAM ITGA4
33 lung disease 29.1 VEGFA MMP9 ICAM1 ELN CRP
34 pulmonary embolism 29.1 VWF SERPINE1 PLAU PLAT MTHFR F5
35 thrombophilia 29.0 VWF SERPINE1 SELP PLAT MTHFR F5
36 hydronephrosis 29.0 VWF VEGFA TIMP1 MMP9 ICAM1 CRP
37 peripheral artery disease 29.0 VWF VEGFA VCAM1 SELP ICAM1 CRP
38 retinal vein occlusion 29.0 VEGFA SERPINE1 MTHFR F5 F2
39 body mass index quantitative trait locus 11 28.9 VEGFA VCAM1 SERPINE1 SELL ICAM1 CRP
40 pulmonary disease, chronic obstructive 28.9 TIMP1 MMP9 MMP1 ITGAM ELN CRP
41 tetralogy of fallot 28.8 VEGFA MTHFR MMP9 ELN CRP
42 coronary heart disease 1 28.8 VWF VCAM1 SERPINE1 SELP PLAT MTHFR
43 synovitis 28.7 VEGFA VCAM1 MMP9 MMP1 ICAM1 CRP
44 varicose veins 28.7 VWF VEGFA TIMP1 PLAT MTHFR MMP9
45 central retinal vein occlusion 28.7 VWF VEGFA PLAT MTHFR F5 F2
46 thrombosis 28.7 VWF VCAM1 SERPINE1 SELP PLAU PLAT
47 vein disease 28.5 VWF VEGFA SERPINE1 PLAT MTHFR ICAM1
48 arteriosclerosis 28.5 VCAM1 TIMP1 SERPINE1 SELP MMP9 ICAM1
49 peripheral vascular disease 28.5 VWF VEGFA VCAM1 TIMP1 SERPINE1 SELP
50 retinal vascular disease 28.4 VEGFA VCAM1 NDP MTHFR ICAM1 CRP
51 homocysteinemia 28.3 VWF VCAM1 SERPINE1 MTHFR F5 F2
52 systemic lupus erythematosus 27.7 VWF VEGFA VCAM1 TIMP1 SERPINE1 SELP
53 cerebrovascular disease 27.3 VWF VCAM1 SERPINE1 SELP SELL PLAT
54 diabetes mellitus 27.0 VWF VEGFA VCAM1 SERPINE1 SELP SELL
55 vascular disease 26.9 VWF VEGFA VCAM1 TIMP1 SERPINE1 SELP
56 multiple sclerosis 10.6
57 fibrinolytic defect 10.6 SERPINE1 PLAT
58 central serous chorioretinopathy 10.6 SERPINE1 PLAT
59 plasminogen activator inhibitor-1 deficiency 10.5 SERPINE1 PLAT
60 cardiac tuberculosis 10.5 SERPINE1 CRP
61 orbital osteomyelitis 10.5 F2 CRP
62 dic in newborn 10.5 SERPINE1 F2
63 small intestine diverticulitis 10.5 F2 CRP
64 autoimmune inner ear disease 10.5 TIMP1 MMP9
65 idiopathic eosinophilic pneumonia 10.5 SELL ITGAM ITGA4
66 cardiogenic shock 10.5 PLAT CRP
67 papillary adenofibroma 10.5 VWF F2
68 synovial angioma 10.5 F2 CRP
69 renal pelvis squamous cell carcinoma 10.5 F2 CRP
70 blue toe syndrome 10.5 F2 CRP
71 emphysematous cholecystitis 10.4 F2 CRP
72 hepatoportal sclerosis 10.4 F2 ELN
73 inflammatory bowel disease 14 10.4 TIMP1 SERPINE1 ICAM1
74 toxicodendron dermatitis 10.4 SELL ICAM1
75 necrotizing gastritis 10.4 F2 CRP
76 platelet aggregation, spontaneous 10.4 VWF SELP PLAT
77 thrombotic microangiopathy 10.4 VWF VEGFA
78 mid-dermal elastolysis 10.4 TIMP1 ELN
79 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 10.4 VWF CRP
80 fungal keratitis 10.4 TIMP1 MMP9
81 intracranial embolism 10.4 PLAT F2 CRP
82 pediatric angiosarcoma 10.4 VWF VEGFA
83 cavernous sinus thrombosis 10.4 F2 CRP
84 pyridoxine deficiency anemia 10.4 VCAM1 F2
85 cardiac tamponade 10.4 PLAT F2 CRP
86 neonatal stroke 10.4 SERPINE1 MTHFR
87 intratubular embryonal carcinoma 10.4 PLAU MMP9
88 arthus reaction 10.4 SELP SELL ICAM1
89 hydrops, lactic acidosis, and sideroblastic anemia 10.4
90 prothrombin-related thrombophilia 10.4 MTHFR F2
91 actinic prurigo 10.4 VCAM1 ITGA4 ICAM1
92 mooren's ulcer 10.4 VCAM1 ITGA4 ICAM1
93 systemic autoimmune disease 10.4 MMP9 CRP
94 paranasal sinus disease 10.4 SERPINE1 PLAU CRP
95 primary thrombocytopenia 10.3 VWF SELP F2
96 qualitative platelet defect 10.3 VWF F2
97 thrombotic thrombocytopenic purpura 10.3 VWF SELP PLAT
98 hepatic veno-occlusive disease 10.3 VEGFA SERPINE1 PLAT
99 active peptic ulcer disease 10.3 VWF F2 CRP
100 infective endocarditis 10.3 SERPINE1 F2 CRP
101 cardiac rupture 10.3 PLAT MMP9 CRP
102 shwartzman phenomenon 10.3 VCAM1 ITGAM ICAM1
103 paracetamol poisoning 10.3 F5 F2
104 cryptogenic organizing pneumonia 10.3 TIMP1 MMP9 CRP
105 sticky platelet syndrome 10.3 SERPINE1 F5
106 lateral sinus thrombosis 10.3 MTHFR F2
107 crescentic glomerulonephritis 10.3 VCAM1 SERPINE1 ICAM1
108 dowling-degos disease 1 10.3
109 dermatitis 10.3
110 pleurisy 10.3 SELL ICAM1 CRP
111 hydrocele 10.3 VEGFA ITGA4 ICAM1
112 heart conduction disease 10.3 PLAT F2 CRP
113 splenic abscess 10.3 F2 CRP
114 carotid artery thrombosis 10.3 VWF SERPINE1 SELP PLAT
115 ascending cholangitis 10.3 F2 CRP
116 coronary thrombosis 10.3 VWF SERPINE1 SELP PLAT
117 immune-complex glomerulonephritis 10.3 VCAM1 SELP ICAM1
118 extrinsic cardiomyopathy 10.3 ITGAM ICAM1 CRP
119 lymphangiosarcoma 10.3 VWF VEGFA
120 apnea, obstructive sleep 10.3 VEGFA SERPINE1 CRP
121 livedoid vasculitis 10.3 SERPINE1 MTHFR F2
122 hemifacial spasm 10.3 VEGFA MTHFR
123 appendicitis 10.3 TIMP1 MMP9 CRP
124 henoch-schoenlein purpura 10.3 VCAM1 ICAM1 CRP
125 glanzmann thrombasthenia 10.2 VWF SELP F2
126 hypertensive retinopathy 10.2 VWF VEGFA CRP
127 acquired angioedema 10.2 F5 CRP
128 bronchiolitis obliterans 10.2 TIMP1 MMP9 CRP
129 lung giant cell carcinoma 10.2 VEGFA TIMP1 MMP9
130 ileus 10.2 ICAM1 F2 CRP
131 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.2
132 lymphedema 10.2
133 cerebral arterial disease 10.2 PLAT MMP9 ELN
134 background diabetic retinopathy 10.2 VEGFA VCAM1 ICAM1
135 spastic entropion 10.2 MMP9 MMP1
136 pericardial effusion 10.2 VEGFA F2 CRP
137 endophthalmitis 10.2 VEGFA ICAM1 CRP
138 bacterial meningitis 10.2 TIMP1 MMP9 CRP
139 exanthem 10.2 VEGFA F2 CRP
140 aortic valve insufficiency 10.2 VWF ELN CRP
141 sorsby fundus dystrophy 10.2 TIMP1 MMP9 ELN
142 oral submucous fibrosis 10.2 TIMP1 MMP9 ELN
143 pediatric multiple sclerosis 10.2 MMP9 ITGA4
144 nodular goiter 10.2 VEGFA ICAM1 CRP
145 alcoholic hepatitis 10.2 ICAM1 F2 CRP
146 bernard-soulier syndrome 10.2 VWF SELP F2
147 dysfibrinogenemia, congenital 10.2 PLAT F5 F2
148 lemierre's syndrome 10.2 MTHFR F2 CRP
149 collagenous colitis 10.2 TIMP1 MMP9 MMP1
150 hemolytic-uremic syndrome 10.2 VWF SELP F2
151 intracranial sinus thrombosis 10.2 MTHFR F2 CRP
152 pleural disease 10.2 VEGFA F2 CRP
153 paresthesia 10.2
154 decubitus ulcer 10.2 VEGFA MMP9 CRP
155 mastoiditis 10.2 MTHFR F2 CRP
156 macular degeneration, age-related, 9 10.2 VCAM1 SELP SELL ICAM1
157 ischemia 10.2 VEGFA SELP PLAT ICAM1
158 light chain deposition disease 10.2 MMP9 MMP1
159 mitral valve stenosis 10.2 VWF SELP F2 CRP
160 rosacea 10.2 VEGFA MMP9 CRP
161 pulmonary edema 10.2 ICAM1 F2 CRP
162 factor v leiden thrombophilia 10.2 MTHFR F5
163 oral lichen planus 10.2 VCAM1 MMP1 ICAM1
164 central retinal artery occlusion 10.2 VEGFA PLAT F2 CRP
165 acalculous cholecystitis 10.2 F2 CRP
166 kawasaki disease 10.1 TIMP1 SELL MMP9 CRP
167 thrombocytosis 10.1 VWF SELP F2 CRP
168 factor x deficiency 10.1 VWF F5 F2
169 factor v deficiency 10.1 VWF F5 F2
170 kaposi sarcoma 10.1
171 adult respiratory distress syndrome 10.1 SERPINE1 F2 ELN
172 mediastinitis 10.1 F5 F2 CRP
173 pulmonary fibrosis 10.1 TIMP1 SERPINE1 MMP9 ELN
174 factor viii deficiency 10.1 VWF F5 F2
175 collagen disease 10.1 VWF ELN CRP
176 factor xi deficiency 10.1 VWF F5 F2
177 peripheral vertigo 10.1 F5 F2 CRP
178 intracranial berry aneurysm 10.1 PLAT MMP9 ICAM1 CRP
179 impotence 10.1
180 odontogenic myxoma 10.1 VEGFA MMP9 MMP1
181 cholesterol embolism 10.1 F2 CRP
182 idiopathic interstitial pneumonia 10.1 VEGFA SERPINE1 ICAM1
183 chronic actinic dermatitis 10.1 MMP9 MMP1 ELN
184 nephrosclerosis 10.1 VEGFA MTHFR F2
185 conjunctivochalasis 10.1 TIMP1 PLAU MMP9 MMP1
186 muscular dystrophy white matter spongiosis 10.1
187 prothrombin deficiency, congenital 10.1 F5 F2
188 acquired immunodeficiency syndrome 10.1 VCAM1 ITGAM ICAM1 CRP
189 endocardium disease 10.1 VWF F2 ELN CRP
190 nutritional deficiency disease 10.1 MTHFR F2 CRP
191 aortic aneurysm 10.1 TIMP1 MMP9 ELN CRP
192 glucose metabolism disease 10.1 VEGFA SERPINE1 ICAM1 CRP
193 quebec platelet disorder 10.1 SERPINE1 SELP PLAU F5
194 arteriovenous malformations of the brain 10.0 VWF VEGFA MMP9 F2
195 heart valve disease 10.0 VWF F2 ELN CRP
196 catastrophic antiphospholipid syndrome 10.0 SERPINE1 MTHFR F5
197 coronary stenosis 10.0 VWF SERPINE1 SELL ICAM1 CRP
198 panniculitis 10.0
199 constipation 10.0
200 eclampsia 10.0 VEGFA SERPINE1 MTHFR F2
201 factor xiii deficiency 10.0 VWF SERPINE1 F5 F2
202 uremia 10.0 VWF ITGAM CRP
203 arteritic anterior ischemic optic neuropathy 10.0 MTHFR F5 F2
204 aortic disease 10.0 TIMP1 MMP9 ELN CRP
205 spinal cord infarction 10.0 MTHFR F5 F2
206 gingival disease 10.0 TIMP1 MMP9 MMP1 CRP
207 preterm premature rupture of the membranes 10.0 TIMP1 MMP9 MMP1 CRP
208 castleman disease 10.0 VEGFA VCAM1 ICAM1 CRP
209 cerebral sinovenous thrombosis 10.0 MTHFR F5 F2
210 atrial fibrillation 10.0 VWF SELP PLAT F2 CRP
211 bullous retinoschisis 10.0 VEGFA F5
212 osteonecrosis 10.0 VEGFA SERPINE1 MTHFR F2
213 cholesteatoma of middle ear 10.0 MMP9 MMP1 ICAM1
214 placental insufficiency 10.0 VWF VEGFA SERPINE1 SELP F2
215 klippel-trenaunay-weber syndrome 10.0
216 leptin deficiency or dysfunction 10.0
217 hydrocephalus 10.0
218 necrobiosis lipoidica 10.0
219 peripheral nervous system disease 10.0
220 neuropathy 10.0
221 taylor's syndrome 10.0
222 porencephaly 10.0 MTHFR F5 F2
223 antithrombin iii deficiency 10.0 MTHFR F5 F2
224 interstitial lung disease 10.0 TIMP1 SERPINE1 MMP9 ICAM1 CRP
225 meningitis 10.0 VEGFA MMP9 ICAM1 CRP
226 polyarteritis nodosa 10.0 VCAM1 SELP SELL ICAM1 CRP
227 hepatic vascular disease 10.0 VWF VEGFA SERPINE1 F2 CRP
228 breast adenocarcinoma 10.0 SERPINE1 PLAU MMP9 MMP1
229 blood protein disease 10.0 VWF VEGFA MTHFR F2
230 placental abruption 9.9 MTHFR F5 F2
231 branch retinal artery occlusion 9.9 VEGFA MTHFR F2 CRP
232 pelvic organ prolapse 9.9 TIMP1 MMP9 MMP1 ELN
233 mitral valve disease 9.9 MMP1 F2 ELN CRP
234 polycythemia vera 9.9 VWF SELP F5 F2
235 aortic aneurysm, familial thoracic 1 9.9 TIMP1 MMP9 MMP1 ELN
236 pneumothorax 9.9 TIMP1 MMP9 MMP1 ELN
237 myelofibrosis 9.9 VEGFA TIMP1 SELP ITGAM CRP
238 endometriosis 9.9 VEGFA TIMP1 PLAU MMP1
239 budd-chiari syndrome 9.9 MTHFR F5 F2
240 pseudoxanthoma elasticum 9.9 VEGFA SELP MMP9 ELN
241 yemenite deaf-blind hypopigmentation syndrome 9.9
242 body mass index quantitative trait locus 1 9.9
243 erysipelas 9.9
244 varicocele 9.9
245 demyelinating disease 9.9
246 cellulitis 9.9
247 systemic scleroderma 9.9
248 elephantiasis 9.9
249 localized scleroderma 9.9
250 leukostasis 9.9 VEGFA VCAM1 SELP SELL ICAM1
251 fibrosarcoma 9.9 TIMP1 SERPINE1 PLAU MMP9 MMP1
252 exfoliation syndrome 9.9 MTHFR MMP1 ELN
253 blood platelet disease 9.9 VWF VEGFA SELP F2 CRP
254 afibrinogenemia, congenital 9.9 VWF SERPINE1 PLAT F5 F2
255 chorioamnionitis 9.9 VEGFA MMP9 MMP1 CRP
256 marantic endocarditis 9.9 VWF PLAT MTHFR F2 CRP
257 cryptogenic cirrhosis 9.9 SERPINE1 MTHFR F5 F2
258 leukocyte adhesion deficiency, type i 9.9 VCAM1 SELP SELL ITGAM ITGA4 ICAM1
259 protein s deficiency 9.9 SERPINE1 MTHFR F5 F2
260 protein c deficiency 9.9 SERPINE1 MTHFR F5 F2
261 legg-calve-perthes disease 9.9 SERPINE1 SELP MTHFR F5
262 grange syndrome 9.9 VWF VCAM1 SELP PLAT MTHFR
263 peritonitis 9.9 SERPINE1 SELP ITGAM ICAM1 F2 CRP
264 von willebrand's disease 9.9 VWF SELP PLAT F5 F2
265 microvascular complications of diabetes 1 9.9 VEGFA VCAM1 TIMP1 MMP9 ICAM1
266 keratoconus 9.8 TIMP1 MMP9 MMP1 ELN
267 exudative vitreoretinopathy 1 9.8 VEGFA NDP CRP
268 cerebral palsy 9.8 TIMP1 MTHFR F5 F2
269 glycogen storage disease 9.8 VWF MTHFR ITGAM CRP
270 colorectal adenoma 9.8 VEGFA MTHFR MMP9 CRP
271 thrombasthenia 9.8 SELP MTHFR F5 F2
272 autoimmune disease 9.8
273 meniere disease 9.8
274 norrie disease 9.8
275 body mass index quantitative trait locus 9 9.8
276 body mass index quantitative trait locus 8 9.8
277 body mass index quantitative trait locus 4 9.8
278 body mass index quantitative trait locus 10 9.8
279 body mass index quantitative trait locus 7 9.8
280 body mass index quantitative trait locus 12 9.8
281 body mass index quantitative trait locus 14 9.8
282 body mass index quantitative trait locus 18 9.8
283 body mass index quantitative trait locus 19 9.8
284 body mass index quantitative trait locus 20 9.8
285 secondary progressive multiple sclerosis 9.8
286 sensorineural hearing loss 9.8
287 osteomyelitis 9.8
288 dermatomyositis 9.8
289 amnestic disorder 9.8
290 sarcoma 9.8
291 chlamydia 9.8
292 lyme disease 9.8
293 goiter 9.8
294 neuritis 9.8
295 ankylosis 9.8
296 tricuspid valve insufficiency 9.8
297 spindle cell sarcoma 9.8
298 congestive heart failure 9.8
299 periostitis 9.8
300 47,xyy 9.8
301 sickle cell disease 9.8
302 cytokine deficiency 9.8
303 aneurysm 9.8
304 anoxia 9.8
305 autonomic dysfunction 9.8
306 chronic pain 9.8
307 systolic heart failure 9.8 VWF TIMP1 MMP9 MMP1 CRP
308 acute myocardial infarction 9.8 VWF SERPINE1 SELP PLAT MMP9 CRP
309 periodontitis 9.8 TIMP1 MMP9 MMP1 ICAM1 CRP
310 lymphangioleiomyomatosis 9.8 VEGFA MMP9 MMP1 ELN
311 intermediate coronary syndrome 9.8 VWF VCAM1 SELP PLAT ICAM1 CRP
312 sickle cell anemia 9.8 VWF VCAM1 MTHFR ICAM1 F2
313 severe pre-eclampsia 9.8 VEGFA VCAM1 MMP9 F5
314 gingivitis 9.8 VEGFA PLAT MMP9 MMP1 ICAM1
315 familial hypercholesterolemia 9.8 TIMP1 MTHFR MMP9 F2 CRP
316 intermittent claudication 9.8 VWF VEGFA SERPINE1 SELP F2 CRP
317 atrial heart septal defect 9.8 PLAT MTHFR F2 ELN CRP
318 acute promyelocytic leukemia 9.8 SERPINE1 SELP PLAU PLAT ITGAM ICAM1
319 carotid artery disease 9.7 TIMP1 SELP PLAT MMP9 MMP1 CRP
320 hemorrhagic disease 9.7 VWF SERPINE1 PLAT F5 F2 CRP
321 pulmonary emphysema 9.7 VEGFA TIMP1 MMP9 MMP1 ELN
322 disseminated intravascular coagulation 9.7 VWF SERPINE1 PLAT F5 F2 CRP
323 takayasu arteritis 9.7 VWF VCAM1 MMP9 ICAM1 F2 CRP
324 diabetes mellitus, insulin-dependent 9.7 VEGFA VCAM1 SELL ITGAM ICAM1 CRP
325 pfeiffer syndrome 9.7
326 cardiac arrhythmia 9.7
327 hypercholesterolemia, familial, 1 9.7
328 lipomatosis, multiple 9.7
329 migraine with or without aura 1 9.7
330 porphyria cutanea tarda 9.7
331 pulmonary hypertension, primary, 1 9.7
332 retinoblastoma 9.7
333 sarcoidosis 1 9.7
334 spinal arachnoiditis 9.7
335 torticollis 9.7
336 vitiligo-associated multiple autoimmune disease susceptibility 6 9.7
337 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.7
338 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.7
339 osteogenic sarcoma 9.7
340 vitiligo-associated multiple autoimmune disease susceptibility 1 9.7
341 sick sinus syndrome 3 9.7
342 myelodysplastic syndrome 9.7
343 human herpesvirus 8 9.7
344 helix syndrome 9.7
345 mucocutaneous ulceration, chronic 9.7
346 deficiency anemia 9.7
347 tendinitis 9.7
348 chlamydia pneumonia 9.7
349 pain agnosia 9.7
350 acrodermatitis chronica atrophicans 9.7
351 non-alcoholic steatohepatitis 9.7
352 hypogonadotropic hypogonadism 9.7
353 pigmentation disease 9.7
354 pleomorphic lipoma 9.7
355 thalassemia 9.7
356 siderosis 9.7
357 meningoencephalitis 9.7
358 leech infestation 9.7
359 arteriovenous malformation 9.7
360 autonomic nervous system disease 9.7
361 ecthyma 9.7
362 allergic hypersensitivity disease 9.7
363 optic neuritis 9.7
364 arachnoiditis 9.7
365 common variable immunodeficiency 9.7
366 tinea pedis 9.7
367 tarsal tunnel syndrome 9.7
368 cerebral atherosclerosis 9.7
369 guillain-barre syndrome 9.7
370 transient global amnesia 9.7
371 porphyria 9.7
372 hypermobility syndrome 9.7
373 sick sinus syndrome 9.7
374 rheumatic disease 9.7
375 calcinosis 9.7
376 status epilepticus 9.7
377 enthesopathy 9.7
378 sensory peripheral neuropathy 9.7
379 angiodysplasia 9.7
380 basal cell carcinoma 9.7
381 papilloma 9.7
382 acrodermatitis 9.7
383 auditory system disease 9.7
384 contact dermatitis 9.7
385 pulmonary tuberculosis 9.7
386 mucinoses 9.7
387 granuloma annulare 9.7
388 myopathy 9.7
389 pustulosis of palm and sole 9.7
390 hypokalemia 9.7
391 familial retinoblastoma 9.7
392 poliomyelitis 9.7
393 infertility 9.7
394 compartment syndrome 9.7
395 mitochondrial myopathy 9.7
396 premenstrual tension 9.7
397 hemarthrosis 9.7
398 chronic fatigue syndrome 9.7
399 pyoderma gangrenosum 9.7
400 lupus erythematosus 9.7
401 psoriasis 9.7
402 dermatophytosis 9.7
403 lichen planus 9.7
404 erythromelalgia 9.7
405 hypertensive encephalopathy 9.7
406 fasciitis 9.7
407 irritable bowel syndrome 9.7
408 hypermobile ehlers-danlos syndrome 9.7
409 48,xyyy 9.7
410 homologous wasting disease 9.7
411 may-thurner syndrome 9.7
412 pure autonomic failure 9.7
413 encephalopathy 9.7
414 headache 9.7
415 cerebrofacial arteriovenous metameric syndrome 9.7
416 superficial siderosis 9.7
417 overgrowth syndrome 9.7
418 pregnancy loss, recurrent 1 9.7 MTHFR F5
419 vascular dementia 9.7 VEGFA MTHFR MMP9 ICAM1 CRP
420 inherited blood coagulation disease 9.7 VWF SELP MTHFR F5 F2
421 macular degeneration, age-related, 1 9.6 VEGFA MMP9 ICAM1 ELN CRP
422 pancreatic adenocarcinoma 9.6 VEGFA TIMP1 PLAU MMP9 MMP1
423 inguinal hernia 9.6 TIMP1 MMP9 MMP1 ITGA4 ICAM1 ELN
424 retinal artery occlusion 9.6 VEGFA SERPINE1 MTHFR F5 F2
425 aortic aneurysm, familial abdominal, 1 9.6 TIMP1 PLAU MMP9 MMP1 ELN CRP
426 thrombophilia due to activated protein c resistance 9.6 VWF SERPINE1 PLAT MTHFR F5 F2
427 nonarteritic anterior ischemic optic neuropathy 9.5 VEGFA MTHFR F5 F2 CRP
428 placenta disease 9.5 VEGFA MTHFR F5 F2 CRP
429 bone inflammation disease 9.5 VEGFA MMP9 MMP1 ITGAM ICAM1 CRP
430 intracranial thrombosis 9.5 VWF SELP PLAT MTHFR F5 F2
431 retinal detachment 9.5 VEGFA TIMP1 NDP MMP9 ELN
432 ischemic colitis 9.5 VEGFA SERPINE1 MMP9 F5 F2 CRP
433 gastroschisis 9.5 MTHFR MMP1 ICAM1 F5 F2
434 pulmonary hypertension 9.5 VWF VEGFA TIMP1 SERPINE1 SELP PLAT
435 kidney disease 9.5 VWF VEGFA VCAM1 SERPINE1 MTHFR CRP
436 myeloma, multiple 9.5 VEGFA VCAM1 MMP9 ITGAM ITGA4 ICAM1
437 behcet syndrome 9.4 SELL MTHFR ICAM1 F5 F2 CRP
438 moyamoya disease 1 9.4 VWF VEGFA MTHFR MMP9 F2 ELN
439 tongue cancer 9.4 VEGFA MMP9 MMP1
440 limb ischemia 9.4 VWF VEGFA SERPINE1 PLAT MMP9 ITGAM
441 pneumonia 9.4 VEGFA SELL MMP9 ITGAM ITGA4 ICAM1
442 portal vein thrombosis 9.4 SERPINE1 SELP PLAT MTHFR F5 F2
443 arthritis 9.3 VEGFA VCAM1 TIMP1 MMP9 MMP1 ICAM1
444 essential thrombocythemia 9.3 VWF VEGFA SERPINE1 SELP MTHFR ITGAM
445 retinal vascular occlusion 9.2 VEGFA SELP MTHFR ICAM1 F5 F2
446 arteries, anomalies of 9.1 VWF VEGFA VCAM1 SERPINE1 SELP PLAT
447 pulmonary fibrosis, idiopathic 9.1 VEGFA VCAM1 TIMP1 SERPINE1 MMP9 MMP1
448 patent foramen ovale 9.1 VWF SERPINE1 PLAT MTHFR F5 F2
449 blood coagulation disease 9.0 VWF VEGFA SERPINE1 SELP MTHFR F5
450 osteoporosis 9.0 VEGFA SERPINE1 NDP MTHFR MMP9 ICAM1
451 cardiovascular system disease 9.0 VWF VCAM1 SERPINE1 SELP PLAT MTHFR
452 eye disease 9.0 VEGFA VCAM1 NDP MMP9 MMP1 ICAM1
453 thrombocytopenia 9.0 VWF SERPINE1 SELP SELL PLAT ITGAM
454 carotid stenosis 9.0 VEGFA VCAM1 SELP MTHFR MMP9 MMP1
455 hellp syndrome 8.9 VWF VEGFA TIMP1 SERPINE1 PLAT MTHFR
456 antiphospholipid syndrome 8.9 VWF VCAM1 SERPINE1 SELP PLAT MTHFR
457 pulmonary artery disease 8.9 VWF VEGFA SERPINE1 SELP PLAT MTHFR
458 coronary artery anomaly 8.9 VEGFA VCAM1 SERPINE1 SELP PLAT MMP9
459 asthma 8.8 VCAM1 TIMP1 SELP SELL PLAU MMP9
460 rheumatoid arthritis 8.8 VEGFA VCAM1 TIMP1 SELL MTHFR MMP9
461 stroke, ischemic 8.8 VWF SERPINE1 SELP SELL PLAT MTHFR
462 diabetes mellitus, noninsulin-dependent 8.6 VWF VEGFA VCAM1 SERPINE1 SELP SELL
463 dilated cardiomyopathy 8.5 VWF VEGFA VCAM1 TIMP1 SERPINE1 MMP9
464 atherosclerosis susceptibility 8.5 VWF VEGFA VCAM1 SERPINE1 SELP PLAT
465 malaria 8.5 VWF VEGFA VCAM1 TIMP1 SERPINE1 SELP
466 heart disease 8.3 VWF VEGFA VCAM1 SERPINE1 SELP PLAT
467 hypertension, essential 7.9 VWF VEGFA VCAM1 TIMP1 SERPINE1 SELP
468 inflammatory bowel disease 7.8 VEGFA VCAM1 TIMP1 SELP SELL MTHFR
469 pre-eclampsia 7.6 VWF VEGFA VCAM1 SERPINE1 SELP SELL
470 myocardial infarction 7.2 VWF VEGFA VCAM1 TIMP1 SERPINE1 SELP

Comorbidity relations with Venous Insufficiency via Phenotypic Disease Network (PDN): (showing 20, show less)


Acute Cystitis Aortic Valve Disease 1
Bronchitis Chronic Pulmonary Heart Disease
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Femoral Vein Thrombophlebitis
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Mitral Valve Disease
Osteoporosis Peripheral Vascular Disease
Post-Thrombotic Syndrome Protein-Energy Malnutrition
Schizophreniform Disorder Tinea Pedis

Graphical network of the top 20 diseases related to Venous Insufficiency:



Diseases related to Venous Insufficiency
Sources

Symptoms & Phenotypes for Venous Insufficiency

About this section

MGI Mouse Phenotypes related to Venous Insufficiency:

45 (showing 11, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.4 CRP F2 F5 ICAM1 ITGA4 MMP9
2 homeostasis/metabolism MP:0005376 10.33 CRP F2 F5 ICAM1 ITGAM MMP1
3 hematopoietic system MP:0005397 10.28 F2 ICAM1 ITGA4 ITGAM MMP9 PLAT
4 growth/size/body region MP:0005378 10.27 F2 F5 ICAM1 MMP9 MTHFR PLAT
5 immune system MP:0005387 10.27 CRP F2 ICAM1 ITGA4 ITGAM MMP1
6 cellular MP:0005384 10.22 ICAM1 ITGA4 ITGAM MMP9 PLAT PLAU
7 mortality/aging MP:0010768 10.1 F2 F5 ICAM1 ITGA4 MMP9 MTHFR
8 integument MP:0010771 10.06 F2 F5 ICAM1 MMP9 MTHFR PLAT
9 neoplasm MP:0002006 9.76 ICAM1 MMP1 MMP9 PLAU SELL SERPINE1
10 nervous system MP:0003631 9.73 F2 F5 ICAM1 ITGAM MMP9 MTHFR
11 respiratory system MP:0005388 9.28 F2 MMP9 PLAT PLAU SELL SELP
Sources

Drugs & Therapeutics for Venous Insufficiency

About this section

Drugs for Venous Insufficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 156, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hesperidin Approved, Investigational Phase 4 520-26-3 53477767
2
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
6
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
7
Coumarin Experimental Phase 4 91-64-5 323
8
Troxerutin Investigational Phase 4 7085-55-4 5486699
9 Heparinoids Phase 4
10 Aminaftone Phase 4
11 Calcium, Dietary Phase 4
12 Anticholesteremic Agents Phase 4
13 Rosuvastatin Calcium Phase 4 147098-20-2
14 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
15 Central Nervous System Depressants Phase 4
16 Anesthetics, Local Phase 4
17 Neurotransmitter Agents Phase 4
18 Anti-Arrhythmia Agents Phase 4
19 Adrenergic Agents Phase 4
20 Sympathomimetics Phase 4
21 Epinephryl borate Phase 4
22 Adrenergic Agonists Phase 4
23 Anti-Asthmatic Agents Phase 4
24 Vasoconstrictor Agents Phase 4
25 Sodium Channel Blockers Phase 4
26 Adrenergic beta-Agonists Phase 4
27 Respiratory System Agents Phase 4
28 Autonomic Agents Phase 4
29 Bronchodilator Agents Phase 4
30 Mydriatics Phase 4
31 Diuretics, Potassium Sparing Phase 4
32 Anticoagulants Phase 4
33 Glucuronyl glucosamine glycan sulfate Phase 4
34 Fibrinolytic Agents Phase 4
35 Hypolipidemic Agents Phase 4
36 Lipid Regulating Agents Phase 4
37 Antimetabolites Phase 4
38 Hypoglycemic Agents Phase 4
39
carbamide peroxide Approved Phase 2, Phase 3 124-43-6
40
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
41
tannic acid Approved Phase 3 1401-55-4
42
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
43
Dalteparin Approved Phase 3 9005-49-6
44
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
45
Becaplermin Approved, Investigational Phase 3 165101-51-9
46
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
47
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
48
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
49 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
50
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
51
Zoledronic Acid Approved Phase 2, Phase 3 118072-93-8 68740
52
Nitric Oxide Approved Phase 3 10102-43-9 145068
53
Thrombin Approved, Investigational Phase 3
54
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
55 Antioxidants Phase 3
56 Protective Agents Phase 2, Phase 3
57 Anti-Inflammatory Agents Phase 2, Phase 3
58 calcium heparin Phase 3
59 Tin Fluorides Phase 3
60 Hormones Phase 2, Phase 3
61 Carboxymethylcellulose Sodium Phase 3
62 Gastrointestinal Agents Phase 2, Phase 3
63 Mitogens Phase 3
64 Heparin, Low-Molecular-Weight Phase 3
65 Angiogenesis Inducing Agents Phase 3
66 Antiemetics Phase 2, Phase 3
67 Methylprednisolone Acetate Phase 2, Phase 3
68 Hormone Antagonists Phase 2, Phase 3
69 Diphosphonates Phase 2, Phase 3
70 Antineoplastic Agents, Hormonal Phase 2, Phase 3
71 Neuroprotective Agents Phase 2, Phase 3
72 glucocorticoids Phase 2, Phase 3
73 Free Radical Scavengers Phase 3
74 Vasodilator Agents Phase 3
75 Hemostatics Phase 3
76 Coagulants Phase 3
77 Grape Approved Phase 2
78
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2
79
Timolol Approved Phase 2 26839-75-8 33624 5478
80
Methyl salicylate Approved, Vet_approved Phase 2 119-36-8 4133
81
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
82
Rivaroxaban Approved Phase 2 366789-02-8
83
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
84
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 2 65-23-6 1054
85
Citric acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
86
Quercetin Experimental, Investigational Phase 2 117-39-5 5280343
87
Horse chestnut Experimental Phase 2
88 Omega 3 Fatty Acid Phase 1, Phase 2
89 Olive Phase 1, Phase 2
90 Micronutrients Phase 2
91 Vitamins Phase 2
92 Trace Elements Phase 2
93 Vitamin B Complex Phase 2
94 Vitamin B9 Phase 2
95 Nutrients Phase 2
96 Vitamin B 6 Phase 2
97 Folate Phase 2
98 Butcher's Broom Phase 2
99 Citrate Phase 1, Phase 2
100 Antihypertensive Agents Phase 2
101 Adrenergic Antagonists Phase 2
102 Adrenergic beta-Antagonists Phase 2
103 Salicylates Phase 2
104 Anti-Inflammatory Agents, Non-Steroidal Phase 2
105
protease inhibitors Phase 2
106 Antithrombins Phase 2
107 HIV Protease Inhibitors Phase 2
108 Serine Proteinase Inhibitors Phase 2
109 Antithrombin III Phase 2
110 Factor Xa Inhibitors Phase 2
111 Antirheumatic Agents Phase 2
112 Platelet Aggregation Inhibitors Phase 2
113 Adjuvants, Immunologic Phase 2
114 Pycnogenols Phase 2
115 Immunologic Factors Phase 2
116 Analgesics Phase 2
117 Analgesics, Non-Narcotic Phase 2
118 Cyclooxygenase Inhibitors Phase 2
119 Antipyretics Phase 2
120
Pyridoxal Experimental, Nutraceutical Phase 2 66-72-8 1050
121
Serine Investigational, Nutraceutical Phase 2 56-45-1 5951
122
Iron Approved, Experimental 7439-89-6, 15438-31-0 23925 27284
123
Sulfadiazine Approved, Investigational, Vet_approved 68-35-9 5215
124
Hyaluronic acid Approved, Vet_approved 9004-61-9 53477741
125
Ticlopidine Approved 55142-85-3 5472
126
Pentoxifylline Approved, Investigational 6493-05-6 4740
127
Silicon Approved, Investigational 7440-21-3 4082203
128
Copper Approved, Investigational 7440-50-8 27099
129
Warfarin Approved 81-81-2 6691 54678486
130
Polidocanol Approved 9002-92-0
131
Polihexanide Approved, Investigational 28757-47-3
132
Amikacin Approved, Investigational, Vet_approved 37517-28-5 37768
133
Teicoplanin Approved, Investigational 61036-62-2
134
Apixaban Approved 503612-47-3 10182969
135 fluindione Approved, Investigational 957-56-2
136
Castor oil Approved, Investigational, Nutraceutical, Vet_approved 8001-79-4
137
Tribenoside Experimental 10310-32-4
138
Dabigatran Investigational 211914-51-1
139
Monensin Experimental, Vet_approved 17090-79-8
140 Castor
141 Antitubercular Agents
142 Chlorhexidine gluconate
143 Antibodies, Antiphospholipid
144 Antibodies
145 Immunoglobulins
146 Antidotes
147 Anti-Bacterial Agents
148 Antibiotics, Antitubercular
149 Anti-Infective Agents, Local
150 Anti-Infective Agents
151 Cathartics
152 Laxatives
153 Complement System Proteins
154 Charcoal
155 Carbopol 940
156 Anesthetics, General

Interventional clinical trials:

(showing 241, show less)
# Name Status NCT ID Phase Drugs
1 A 6-week, Open, Multicentre Safety Trial to Evaluate the Tolerability Profile of Antistax® Film Coated Tablets (Extr. Vitis Viniferae Siccum), 360 mg/Day Per os, in Male and Female Patients Suffering From Chronic Venous Insufficiency Completed NCT02184234 Phase 4 Antistax film coated tablets
2 Evaluate the Efficacy and Safety of Esarin Gel in the Treatment of Chronic Venous Insufficiency or Varicose Vein Combine With Superficial Vein Thrombophlebitis in Outpatient Completed NCT02346058 Phase 4 Esarin Gel
3 The Fate Of Calf Perforators After Endovenous Laser Ablation Of Saphenous Veins Completed NCT01458795 Phase 4
4 Multicenter, Prospective, Randomized, Double-Blind Study to Assess the Therapeutic Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency Completed NCT00835822 Phase 4 Venocur Triplex®;placebo
5 Gliding Aids for Medical Compression Stockings - Practicability in Elderly Patients With Chronic Venous Insufficiency Completed NCT01432795 Phase 4
6 Evaluation of Efficacy and Safety of the Fixed-dose Combination of Coumarin and Troxerutin (Venalot®) Versus Placebo in the Symptomatic Treatment of Chronic Venous Insufficiency - VENACT Completed NCT01848210 Phase 4 Coumarin/troxerutin;Placebo
7 Randomized Double-blind Trial Between Clinical and Endovascular Treatment in Patients With Advanced Chronic Venous Insufficiency and Iliac Venous Obstruction Completed NCT02149212 Phase 4 Phlebotonic
8 Clinical Non-inferiority Study Between Diosmin 600 mg Tablets and Diosmin 900 mg + Hesperidin 100 mg Tablets in Symptomatic Chronic Venous Insufficiency After 6 Months of Treatment: Single-blind, Randomized, Parallel Group Study Completed NCT03471910 Phase 4 Diosmin;Diosmin / Hesperidin
9 SocknLeg - a User Friendly Medical Compression Study of a Modified Application of a Medical Device Completed NCT02621632 Phase 4
10 The Effect of Neuromuscular Electrical Therapy on Pain in Patients With Venous Ulcers: a Controlled Clinical Trial Completed NCT01372020 Phase 4
11 Radiofrequency Ablation vs Laser Ablation of the Incompetent Greater Saphenous Vein: A Prospective Randomized Trial Completed NCT02236338 Phase 4
12 A Pilot Trial of the Use of ReCell® Autologous Cell Harvesting Device for Venous Leg Ulcers Completed NCT01743053 Phase 4
13 Study of Antiinflammatory Effects of Detralex (Daflon) in Patients With Chronic Venous Disease Completed NCT01654016 Phase 4 Detralex
14 A Randomized Triple-blind Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Sclerotherapy in Treatment of Reticular Veins at the Lower Limbs. Completed NCT02054325 Phase 4 Polidocanol with Glucose;Glucose
15 Polidocanol Versus Glucose For Sclerotherapy Treatment Of Telangiectasia Of The Lower Limbs: Protocol For A Randomized, Controlled Clinical Trial Completed NCT02657252 Phase 4 Glucose;Polidocanol with Glucose
16 Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event Recruiting NCT03988101 Phase 4 Rosuvastatin 20mg;Control
17 The Efficacy of Rivaroxaban With Diosmine in the Long-term Treatment of Acute Proximal Deep Vein Thrombosis Active, not recruiting NCT03413618 Phase 4 Rivaroxaban;Diosmin
18 A Randomised Clinical Trial Comparing Endovenous Laser Ablation and Mechanochemical Ablation (ClariVein®) in the Management of Superficial Venous Insufficiency Active, not recruiting NCT02627846 Phase 4 Lidocaine with 1:200,000 epinephrine solution;Lidocaine with 1:200,000 epinephrine solution;Sodium Bicarbonate;Sodium Tetradecyl Sulphate
19 Radiofrequency Ablation vs. Laser Ablation of the Incompetent Small Saphenous Vein: A Prospective Randomized Trial Terminated NCT02248740 Phase 4
20 Prospective Evaluation of the Quality of Life of Patients With Post-thrombotic Syndrome Who Receive Compression Therapy and Sulodexide — SQUARES Study Terminated NCT02512601 Phase 4 Sulodexide
21 A Randomized Trial of the Flexitouch Compression System as an Adjunctive Treatment for Venous Stasis Ulcer Terminated NCT00534937 Phase 4
22 A Randomised Clinical Trial Comparing Standard Cannula Delivered Foam Sclerotherapy, Catheter Directed Foam Sclerotherapy and ClariVein® Mechanochemical Ablation in the Management of Superficial Venous Insufficiency. Withdrawn NCT02010437 Phase 4 Sodium Tetradecyl Sulphate (STS)
23 A Clinical Multicenter, Phase III, Prospective, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon Unknown status NCT01477281 Phase 3 Daflon;Venaflon (Diosmin and Hesperidin)
24 Study Clinical, Multicenter,Phase III,Prospective,Randomized,Comparative Double Blind/Double-dummy to Assess the Efficacy and Tolerability of the Use of Varicell in Reducing the Symptoms Caused by Chronic Venous Insufficiency and Hemorrhoidal Syndrome When Compared With Daflon Unknown status NCT01321619 Phase 3 Daflon;Varicell placebo
25 Comparative Efficacy of Two Preparations of the Association Diosmin (450 mg) + Hesperidin (50 mg) in the Treatment of Chronic Venous Insufficiency (CVI) Unknown status NCT01110512 Phase 3 Flavonid;Daflon
26 A Comparative Study to Assess the Efficacy and Safety of Endolex Forte vs Diosmin and Hesperidin in Reducing the symptomatoLogy of Patients With ChronIc VeNous Insufficiency Between Functional Classes CEAP 1-4, During a Period of 6 Months Unknown status NCT02927483 Phase 3
27 A Prospective, Multi-Centre, Double Blind, Randomized, Placebo Controlled Trial to Evaluate the Safety and Efficacy of ICXP007 in a Phase III Trial With Four-Layer Therapeutic Compression, for the Treatment of Non-Infected Skin Leg Ulcers, Due to Venous-Insufficiency Unknown status NCT00232973 Phase 3 ICXP007
28 Efficacy of Autologous Platelet-Rich Plasma in the Treatment of Vascular Ulcers in Primary Care: Clinical Trial Phase III Unknown status NCT02213952 Phase 3 Platelet-Rich Plasma
29 Randomized Single Center Comparative Study of the Treatment of Insufficient Greater Saphenous Vein: Surgery vs Ultrasound Guided Sclerotherapy With Foam and Endovenous Laser Therapy Unknown status NCT00529672 Phase 3
30 A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency Completed NCT02191254 Phase 3 Antistax®;Placebo
31 A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax Film-coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency. Completed NCT00292435 Phase 3 Read vine leaf extract (AS 195)
32 Prospective, Randomized and Explorative Controlled Study About Influences of Compression Stockings on Skin's Barrier Function at Patients With Chronic Venous Insufficiency Completed NCT00196443 Phase 2, Phase 3
33 A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 720 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency Completed NCT00855179 Phase 3 Red vine leaf extract (AS 195);Placebo
34 Clinical Study of BNS003 on Swelling Due to Disorder of Leg Venous Reflux Completed NCT02211898 Phase 3 BNS003
35 Evaluation of the Efficacy of Spa Treatment for Prevention of Leg Ulcers in Advanced Chronic Venous Insufficiency. Completed NCT00838500 Phase 3 Immediate spa treatment;Late spa treatment
36 Crenobalneotherapy in the Treatment of Chronic Venous Insufficiency. A Randomized Clinical Trial. Completed NCT01956318 Phase 3
37 Efficacy on Volume Reduction and Tolerance of Progressiv' Medical Compressive Therapy (MCT) V0322 BC in Patients With Chronic Venous Oedema. International, Multicentric, Randomised, Controlled, Double Blind Study, in Two Parallel Groups v0322 bc Versus Placebo Completed NCT01402921 Phase 3
38 Treatment of Greater Saphenous Vein (GSV) Insufficiency Using Echo-Guided Sclerotherapy With Lauromacrogol 400 Foam –Comparative Study of 3% Versus 1% Concentration. Completed NCT00348764 Phase 3 lauromacrogol
39 A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2 Completed NCT01737762 Phase 3
40 Deep Venous Thrombosis. Long-Term Results After Treatment With Either Low-Molecular -Weight Heparin or Unfractionated Heparin. Examinations of the Venous System. Completed NCT00628576 Phase 3 unfractionated heparin;Tinzaparin (Leo)
41 Double Blind Randomized Controlled Trial of Recombinant Human Platelet Derived Growth Factor-BB Gel (Regranex Gel®) Versus Hydrogel (Duoderm Hydrogel®) for Healing of MARTORELL's Hypertensive Leg Ulcers. ERAN Trial. Completed NCT00970697 Phase 3 becaplermin gel;Duoderm Hydrogel™
42 Zoledronic Acid or Methylprednisolone in the Management of Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus: A Randomized, Double-blind, Placebo Controlled Trial Completed NCT03289338 Phase 2, Phase 3 Zoledronic Acid;Methylprednisolone;Placebos
43 Double Blind, Randomized, Placebo Controlled Clinical Trial for the Treatment of Diabetic Foot Ulcers, Using a Nitric Oxide Releasing Patch: PATHON Completed NCT00428727 Phase 3 Controlled nitric oxide releasing patch;placebo patch
44 The MUFFIN-PTS Trial: Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome Not yet recruiting NCT03833024 Phase 3 Micronized Purified Flavonoid Fraction;Placebo
45 A Phase 3 Randomized Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers (EU) Terminated NCT01853384 Phase 3
46 Clinical Evaluation of the Safety and Effectiveness of Topical Autologous Platelet Gel (APG) for the Treatment of Lower Extremity Chronic Venous Insufficiency Ulcers. A Multicenter, Randomized, Controlled Clinical Trial Withdrawn NCT00273234 Phase 3
47 A Prospective, Randomized, Controlled, Multi-Center, Double Blind Study of ClariVein RES for Treatment of Venous Insufficiency Associated With Incompetent Saphenous Veins Due to Superficial Venous Reflux Unknown status NCT03311269 Phase 2 Sodium Tetradecyl Sulfate 1% Injection;Sodium Tetradecyl Sulfate 3% Injection
48 Endovenous Treatment of the Saphenous Vein With Biolitec 1470nm Laser Versus Vnus Closure Fast Unknown status NCT01972633 Phase 1, Phase 2
49 Phase 1 and 2 Study on the Efficacy and Side Effects of Olive Oil and Omega 3 Local Treatment in Stasis Dermatitis Unknown status NCT00421161 Phase 1, Phase 2 olive oil and omega 3 in a combined cream
50 Efficacy Study of a Peristaltic Pulse Pneumatic Device in the Treatment of Claudication Unknown status NCT01007604 Phase 2
51 A Prospective Double Blind Randomized Controlled Trial Of Electrocoagulation Versus Radiofrequency Treatment Of The Great Saphenous Vein In Patients With Varicose Veins. Unknown status NCT02139085 Phase 2
52 NON-HEALING ULCERS WITHOUT CRITICAL LIMB ISCHEMIA (NEWLI-Trial): A Single Center Pilot Trial on the Efficacy of an Endovascular Approach for Treatment of Non-healing Lower Limb Ulcers in Patients Presenting With a Mild to Moderate Peripheral Artery Disease Unknown status NCT01666093 Phase 2
53 An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Unknown status NCT02587715 Phase 1, Phase 2
54 A Phase II Randomized Study to Evaluate the Safety of the Compression Test Device Using Intermittent Pneumatic Compression Mode in Subjects With Venous Insufficiency and Oedema Completed NCT00732823 Phase 2
55 The Ability of Antistax® to Improve Chronic Venous Insufficiency (CVI) I and II in Male and Female Patients: a Dose Response Study Completed NCT02191280 Phase 2 Antistax®, low dose;Antistax®, high dose;Placebo
56 A 17 Week, Randomised, Double-blind, Placebo Controlled Cross-over Trial to Evaluate the Efficacy of Antistax® Film Coated Tablets (Extr. Vitis Vinifera Siccum), 360 mg/Day p.o. in Improving Microcirculation of the Skin in the Leg of Male and Female Patients Suffering From Chronic Venous Insufficiency Completed NCT02191163 Phase 2 Antistax®;Placebo
57 Endovascular Correction of Chronic Cerebrospinal Venous Insufficiency (CCSVI) and Evaluation of Influence of These Treatments on the Symptoms of Multiple Sclerosis Completed NCT01264848 Phase 1, Phase 2
58 Physical Conditioning in Management of Chronic Venous Insufficiency Completed NCT00013273 Phase 2
59 Evaluation of DermStream(tm) - an Irrigation Product for Chronic Wound Management Completed NCT00310752 Phase 1, Phase 2
60 Phase I/II Interventional Clinical Trial of Balloon Venoplasty for Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis Patients Completed NCT01864941 Phase 1, Phase 2
61 A Randomized, Parallel Group, Controlled Study to Assess the Efficacy and Safety of NMBM in the Treatment of Subjects With a Post-cellulitis and Venous Leg Ulcer Completed NCT01770509 Phase 1, Phase 2
62 The Efficacy of Red Vine Leaf Extract, Butcher's Broom, Horse Chestnut and Vitamin B6 on the Quality of Life in Females With Chronic Venous Insufficiency Completed NCT02498327 Phase 2
63 The Efficacy of Red Vine Leaf Extract, Butcher's Broom, Horse Chestnut and Vitamin B6 in the Treatment of Symptoms Associated With Chronic Venous Insufficiency Completed NCT02483962 Phase 2
64 A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Venous Stasis Ulcers Completed NCT00832091 Phase 2 Thymosin Beta 4;Placebo
65 Topical Timolol Benefit in Venous Ulcers Completed NCT02422017 Phase 2 Timolol
66 Preventing Venous Leg Ulcers With Cryotherapy: A Randomized Clinical Trial Completed NCT01509599 Phase 1, Phase 2
67 Micro-mobile Foot Compression Device to Improve Motor-function in People With Diabetes and Loss of Protective Sensation Completed NCT03135535 Phase 2
68 Safety and Efficacy Study for the Use of Extracorporeal Shockwaves in the Treatment of Chronic Soft Tissue Wounds Completed NCT00545896 Phase 2
69 Feasibility and Safety and Evaluation of the Potential Efficacy of Autologous Platelet-rich Plasma in the Treatment of Vascular Venous Ulcers Compared to Moist Wound Care in a Primary Care Setting Completed NCT01817218 Phase 1, Phase 2 Platelet Rich Plasma
70 An Open Label Multicenter Safety Study of the Varisolve® Procedure for the Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt Completed NCT00442364 Phase 2 Polidocanol (1%) Microfoam (Varisolve)
71 Community Randomised Control Trial of the Effectiveness of Two Compression Bandaging Technologies Completed NCT00202267 Phase 2
72 Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers: a Two-arm, Double-blind, Placebo-controlled, Randomized Controlled Trial. Recruiting NCT03154619 Phase 2 0.1% TR 987;Placebo gel
73 Novel Offloading for Diabetic Foot Ulcers With PulseFlow: A Prospective Study Recruiting NCT02783066 Phase 2
74 Monitoring and Managing Newly Healed Chronic Leg and Foot Ulcer Skin Temperature: A Cooling Intervention (MUSTCOOL) to Prevent Ulcer Recurrence Recruiting NCT02626156 Phase 2
75 A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Local Tolerability of Crisaborole Ointment, 2%, in Adult Participants With Stasis Dermatitis Without Active Skin Ulceration Not yet recruiting NCT04091087 Phase 2 crisaborole ointment
76 Double Blind Randomized Clinical Trial Comparing Pycnogenol Versus Placebo for Pigmentation Prevention After Treatment With Varicose Veins With Foam Sclerotherapy Not yet recruiting NCT04203043 Phase 2 Pycnogenol Oral Product
77 Aspirin® Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis in Patients With Post-thrombotic Syndrome a Multi-center, International, Randomized, Open Label, Controlled Trial Not yet recruiting NCT04128956 Phase 2 Aspirin 100mg
78 A PRELIMINARY OPEN CLINICAL STUDY, TO ASSESS THE SAFETY AND EFFICACY OF RPh201 APPLIED TOPICALLY FOR THE TREATMENT OF HARD TO HEAL CHRONIC ULCERATED WOUNDS Terminated NCT01429519 Phase 1, Phase 2 RPh201, botanical drug product
79 An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Terminated NCT02418325 Phase 1, Phase 2
80 A Phase 1a, Open Label, Single Dose, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Normal Volunteers Given Punch Skin Biopsies Unknown status NCT00916292 Phase 1 FGF-1 141;FGF-1 141
81 Study on the Effect of Kinesio Taping on Bioelectrical Activity of Gastrocnemius Muscles and Range of Ankle Motion in Post-menopausal Women With Chronic Venous Insufficiency Completed NCT01501188 Phase 1
82 Deep Diabetic Foot Wound Treatment With Hydrogel Including 3% Sodium Pentaborate Pentahydrate Recruiting NCT02241811 Phase 1 3% Sodium Pentaborate Pentahydrate;Placebo
83 Phase I Open-label, First-in-human Study to Evaluate Feasibility and Safety of Tissue Engineered Veins in Patients With Chronic Venous Insufficiency Not yet recruiting NCT03784131 Phase 1 P-TEV
84 The Clinical Research of Surgery on Primary Chronic Venous Insufficiency Unknown status NCT00931424
85 Compliance of Compression Therapy in Healed Venous Ulcerations Unknown status NCT01680809
86 A Confirmatory Study to Evaluate the Safety and Efficacy of Cryopreserved Bilayered Cellular Matrix (ORCEL) for the Treatment of Venous Ulcers Unknown status NCT00270972
87 Venous Pressure Measurement of the Great Saphenous Vein Using Controlled Compression Ultrasound in Healthy Persons and Patients With Chronic Venous Disease as a New Non Invasive Method for Investigation of the Pathophysiology in Primary Varicose Veins Unknown status NCT01000909
88 Safety and Primary Efficacy of the External Synchronized Vein Valve (ESVV) in Treatment of Chronic Venous Insufficiency (CVI) Sequel - A Pilot Study Unknown status NCT01346553
89 Venous Obstruction in Neurodegenerative Disorders Research Registry Unknown status NCT01593358
90 3-4 Year Outcomes Following Endovenous Steam Ablation of the Saphenous Veins for the Treatment of Venous Insufficiency Unknown status NCT02944331
91 Prospective Multicentric Randomised Trial Between Radiofrequency Ablation With VNUS Closure Fast ® and Endovenous Ablation With 1470 nm Diod Laser and Tulip Fiber ® for Treatment of Primary Venous Insufficiency. Unknown status NCT01722019
92 Prospective, Single-arm, Single Center, Pilot Study of Vascular Ultrasound Imaging Used as an Adjunct to Intravascular Ultrasound for Diagnosing Iliac Vein Obstruction Unknown status NCT02240914
93 Aqua Therapy to Lower Adverse and Negative Effects of Deep Vein ThrombosIs and Post Thrombotic Syndrome Unknown status NCT02553720
94 Development and Validation of a Limb Volumetry Technique Applicable in Daily Clinical Practice Using Self Positioning 3D Laser Scanning:Reproductibility and Comparison to the Reference Method Unknown status NCT01574911
95 Radiographic and Intravascular (IVUS) Evaluation of Venous Morphology During CCSVI Treatment Unknown status NCT01593891
96 Venous Ulcer: Endovenous Radiofrequency Treatment of Insufficient Perforating and Saphenous Veins Versus Multilayer Compression Bandaging - Randomized Controlled Clinical Trial Unknown status NCT03293836
97 Randomized Trial Comparing a Dual Action Pneumatic Compression System Against Multi-Layer Bandaging Systems: A Non-inferiority Study Unknown status NCT02680834
98 Ecchymosis and Coldness in Patients With Varicose Vein: Multicenter Study of Modified VEIN-Sym QoL Assessment Unknown status NCT03384355
99 Long Term Natural History of PTS and Other Adverse Outcomes After Venous Thromboembolism in the Optimev Study (SPOT) Unknown status NCT03054727
100 Color Doppler U/S vs MSCT Venography in the Diagnosis of May-Thurner Syndrome Unknown status NCT03262987
101 Clinical Trial : Terminal Axial Perforator Interruption Reflux Source (TAPIRS ) Plus Adjustable Compression System in Treatment of Venous Leg Ulcers Versus Multilayer Bandage Treatment Unknown status NCT02798445
102 Local Endogenous Biomarkers in the Later Stages of Chronic Venous Disease Versus Controls During Gravitational Stress, Prolonged Elevation Recovery and Compression Unknown status NCT02662127
103 Vascular Abnormalities in Idiopathic Parkinson's Disease Unknown status NCT02045420
104 Study to Evaluate Polyheal-1 in Treatment of Recalcitrant Wounds Unknown status NCT00552643
105 Randomized Clinical Trial to Determinate the Effectiveness and Safety of Plasma Rich Growth Factors (PRGF) in Venous Ulcers Treatment Unknown status NCT01491438
106 Non-Invasive Management of Chronic Venous Insufficiency Completed NCT00950378
107 Manual Lymphatic Drainage in Chronic Venous Insufficiency: a Randomized Controlled Trial Completed NCT01899482
108 The Effects of Compression Stockings on Pressure Parameters in Patients With Chronic Venous Insufficiency Completed NCT01558024
109 REVITIVE for the Treatment of Patients With Venous Insufficiency Completed NCT02114307
110 Transient Elastography DEdicated to Cosmetology And Dermatology (TEDECAD) Completed NCT02061254
111 Doppler Sonography, Magnetic Resonance Venography, Air-plethysmography in the Non-invasive Diagnostics of Chronic Cerebrospinal Venous Insufficiency (CCSVI) Completed NCT01425554
112 Evaluation of a Dual Action Pneumatic Compression Device: Patient Ease of Use and Comfort Completed NCT02015221
113 The Effectiveness of Exercise Training in Venous Insufficiency Completed NCT03755180
114 Single Center Prospective Study Evaluating the Safety of Progressive Compressive Stockings for the Treatment of Venous Insufficiency in Patients With Peripheral Arterial Disease Completed NCT02431819
115 Preventing the Development of Venous Insufficiency in Pregnant Women Through Use of Compression Stockings: A Randomized Pilot Study Completed NCT01793194
116 Obtaining and Storing Blood Samples and Debridement Samples for Wound Related Research Completed NCT00762697
117 The Sapheon Closure System Feasibility Study Completed NCT01603433
118 Dosing of Electrical Stimulation in Venous Insufficiency Completed NCT03850496
119 VEINEX : Venous Investigations During Exercise Completed NCT02689557
120 New Combined Laser Therapy in Patients With Trophic Ulcers of Lower Extremities and Chronic Venous Insufficiency Completed NCT03104985
121 Comparative Randomized Clinical Study to Evaluate the Efficacy of Radiofrequency vs Surgical Technique of Internal Saphenous Vein Stripping and CHIVA Technique in the Treatment of Chronic Venous Insufficiency. Completed NCT02454452
122 A Comparison of the Party Balloon Assisted Valsalva With Conventional Valsalva Maneuver in Diagnosis of Superficial Venous Valvular Reflux of Lower Limb Completed NCT02051439
123